Rijksinstituut voor Ziekte- en Invaliditeitsverzekering
- Research works
- 62 ▲ 41% vs 2013–17
- Citations
- 703 11.3 per fractional work
- Top-10% rate
- 9.8% record average 16.5%
- Open access
- 47% world 28%
Not ranked overall: Rijksinstituut voor Ziekte- en Invaliditeitsverzekering is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 6.1×. Every wedge is a field page.
- Economics, Econometrics and Finance 6.1×
- Health Professions 6.0×
- Immunology and Microbiology 3.9×
- Social Sciences 2.0×
- Medicine 1.6×
- Chemical Engineering 0.9×
- Environmental Science 0.7×
- Agricultural and Biological Sciences 0.5×
- Psychology 0.4×
- Earth and Planetary Sciences 0.2×
- Computer Science 0.2×
- Biochemistry, Genetics and Molecular Biology 0.1×
- Neuroscience 0.1×
- Decision Sciences 0.1×
- Physics and Astronomy 0.1×
- Materials Science 0.1×
- Engineering 0.0×
Which keywords describe research at Rijksinstituut voor Ziekte- en Invaliditeitsverzekering?
By fractional works in all years, weighted toward what it does more of than the world: Quality of Life, Public Health, Primary Care, Cost-effectiveness Analysis, Health Utility Measures, Healthcare Policy, Pharmaceutical Industry and Drug Development Costs.
- Social Innovation
- Medical Ethics
- End-of-Life Care
- Patient Safety
- Choosing Wisely
- Quality Assessment
- Practice Recommendations
- Guideline Development
- Off-Label Drug Use
- Chronic Disease Management
- Self-Determination
- Risk Factors
- Clinical Guidelines
- Universal Health Coverage
- Social Determinants of Health
- Generic Drugs
- Pharmaceutical Industry
- Epidemiology
- Cost-effectiveness Analysis
- Public Health
- Quality of Life
- Primary Care
- Health Utility Measures
- Healthcare Policy
- Drug Development Costs
- Quality Improvement
- Inequalities
- Clinical Trials
- Economic Development
- Patient Engagement
- Universal Design for Learning
- Adverse Drug Reactions
- Pediatric Pharmacokinetics
- Healthcare Communication
- Public Health Policy
- Quality of Care
- Low-Value Care
- Cyclodextrins
- Health Disparities
- Patient Rights
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Quality of Life8▲ 9.3×13 topics
- Public Health5▲ 6.2×17 topics
- Primary Care4▲ 17×8 topics
- Cost-effectiveness Analysis4▲ 79×1 topic
- Health Utility Measures4▲ 79×1 topic
- Epidemiology3▲ 1.26×24 topics
- Healthcare Policy3▲ 58×2 topics
- Pharmaceutical Industry3▲ 107×2 topics
- Drug Development Costs3▲ 167×1 topic
- Generic Drugs3▲ 167×1 topic
- Quality Improvement3▲ 20×6 topics
- Social Determinants of Health2▲ 17×3 topics
- Inequalities2▲ 95×1 topic
- Universal Health Coverage2▲ 95×1 topic
- Clinical Trials2▲ 5.3×6 topics
- Clinical Guidelines2▲ 9.8×4 topics
- Economic Development2▲ 4.3×3 topics
- Risk Factors2▲ 2.8×11 topics
- Patient Engagement2▲ 29×2 topics
- Self-Determination2▲ 180×1 topic
- Universal Design for Learning2▲ 180×1 topic
- Chronic Disease Management2▲ 16×3 topics
- Adverse Drug Reactions1▲ 35×2 topics
- Off-Label Drug Use1▲ 60×1 topic
- Pediatric Pharmacokinetics1▲ 60×1 topic
- Guideline Development1▲ 67×1 topic
- Healthcare Communication1▲ 26×2 topics
- Practice Recommendations1▲ 67×1 topic
- Public Health Policy1▲ 11×3 topics
- Quality Assessment1▲ 10×2 topics
- Quality of Care1▲ 25×2 topics
- Choosing Wisely1▲ 89×1 topic
- Low-Value Care1▲ 89×1 topic
- Patient Safety1▲ 14×4 topics
- Cyclodextrins1▲ 70×1 topic
- End-of-Life Care1▲ 11×2 topics
- Health Disparities1▲ 8.2×3 topics
- Medical Ethics1▲ 9.7×3 topics
- Patient Rights1▲ 17×2 topics
- Social Innovation1▲ 13×1 topic
Which research topics does Rijksinstituut voor Ziekte- en Invaliditeitsverzekering publish most on?
By volume in 2022–2025: Social Sciences and Governance, Health Systems, Economic Evaluations, Quality of Life, Health Literacy and Information Accessibility and Pharmaceutical Economics and Policy.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Social Sciences and Governance Urban Studies 1 works
- 2 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 1 works
- 3 Health Literacy and Information Accessibility General Health Professions 1 works
- 4 Pharmaceutical Economics and Policy Economics and Econometrics 0 works
- 5 Healthcare Systems and Public Health Epidemiology 0 works
- 6 Human Health and Disease Pediatrics, Perinatology and Child Health 0 works
- 7 Social Media in Health Education Health 0 works
- 8 Natural Resources and Economic Development General Economics, Econometrics and Finance 0 works
- 9 Central European Literary Studies Anthropology 0 works
- 10 Language and Culture Linguistics and Language 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Rijksinstituut voor Ziekte- en Invaliditeitsverzekering's research output changed?
Output in 2018–2022 was 41% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Brussels
- Vrije Universiteit Brussel
- Université Libre de Bruxelles
- Cliniques Universitaires Saint-Luc
- Erasmus Hospital
- European Commission
- UCLouvain Saint-Louis Brussels
- European Union of Medical Specialists
- European Union
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.